Amgen's new research and development facility in San Francisco. (courtesy photo) The Federal Trade Commission has put a pause on its lawsuit against Thousand Oaks-based Amgen’s acquisition of Horizon Therapeutics to allow time for the FTC to consider a settlement. If a settlement is agreed to, then this legal saga between Amgen and the FTC…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
